Mirum Pharmaceuticals (MIRM) Following Strong EXPAND Data Looks Undervalued But Is It Priced In

Mirum Pharmaceuticals (MIRM) has put fresh clinical data at the center of the story. The Phase 3 EXPAND trial of LIVMARLI in ultra rare cholestatic liver diseases hit its primary and all prespecified secondary endpoints.

For Mirum Pharmaceuticals, the fresh EXPAND data lands after a choppy stretch in the market, with the share price down 12.38% over the past 30 days and 28.81% over 90 days, yet still positive year to date with a 10.23% share price return. At a latest share price of $86.06, momentum has picked up again in the very short term with a 7 day share price return of 5.69%, while longer run investors are sitting on a 19.25% total shareholder return over 1 year and a very large 5 year total shareholder return. This suggests that traders are reassessing both the growth potential and risk profile as LIVMARLI progresses.

Spot emerging rare-disease momentum beyond Mirum Pharmaceuticals by scanning our hand-picked 20 high quality undiscovered gems that pair specialist pipelines with stronger fundamentals.

Fresh EXPAND data and a share price near $86 put Mirum Pharmaceuticals at a sizeable discount to analyst targets and intrinsic estimates. Is this caution protecting you from risk, or leaving too much upside on the table?

Most Popular Narrative: 41% Undervalued

Analysts following Mirum Pharmaceuticals see a wide gap between the latest close at $86.06 and a narrative fair value of $145.79, and they are tying that valuation to a very specific rare-disease expansion story.

The expanding addressable patient population for Mirum's therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth.

See why 12 investors see Mirum Pharmaceuticals as 41% undervalued.

Result: Fair Value of $145.79 (UNDERVALUED)

Still, Mirum Pharmaceuticals leans heavily on LIVMARLI and faces shifting drug pricing and reimbursement policies that could pressure revenue concentration and long term profitability.

Find out about the key risks to this Mirum Pharmaceuticals narrative.

Next Steps

Mixed signals on Mirum Pharmaceuticals so far, right, with both enthusiasm and worries on display. Move quickly, review the full picture, and weigh the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Mirum Pharmaceuticals?

Consider broadening your search beyond a single rare-disease story, as the wider market contains many potential opportunities that can be filtered by quality, income and downside protection using the Simply Wall Street Screener.

• Target resilient balance sheets by reviewing companies on our list of solid balance sheet and fundamentals (25 results) that combine financial strength with the potential to handle tougher conditions without placing excessive strain on their finances.
• Hunt for mispriced quality by scanning the 29 high quality undervalued stocks, which highlights companies where fundamentals and current prices appear out of sync.
• Protect your downside by focusing on stability first through the 31 resilient stocks with low risk scores, which filters for businesses with lower risk scores and sturdier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com